(616 | Kb)

Explain the specific (toxicities) that led to these discontinuations. Compare these results to more recent ibrutinib studies .

: Patients in clinical trials were generally younger, with a mean age of 58 compared to 61 in this real-world group. (616 KB)

The study highlighted a few differences between "real-world" patients and those in trials: Explain the specific (toxicities) that led to these

: Investigating approaches where patients only take the drug for a set period, especially if they achieve a complete response, to avoid unnecessary long-term exposure and side effects. If you'd like, I can: (616 KB)

Toxicities and outcomes of 616 ibrutinib-treated patients in ... - PMC